Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 3/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL202832 | 0.99 | PDE4B (0.51) | PDE4BARMAP3K5PDE4APDE4C | |
| SCHEMBL4940189 | 0.88 | PDE4A (0.55) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4119970 | 0.86 | SLC6A2 (0.48) | PDE4BARSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4227931 | 0.84 | SLC6A2 (0.43) | MAP3K5TBK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2693669 | 0.83 | HRH3 (0.61) | PDE4BARCYP11B2 | |
| Hydrochloric Acid SCHEMBL70445 | 0.82 | SLC6A2 (0.42) | ARMAP3K5TBK1SLC6A2SLC6A4 | |
| SCHEMBL225826 | 0.81 | SLC6A2 (0.49) | MAP3K5SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12409078 | 0.80 | PDE4B (0.56) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1560104 | 0.80 | PDE4B (0.45) | PDE4BARPDE4APDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL16818301 | 0.79 | SLC6A2 (0.48) | MAP3K5SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| EP-2303276-B1 | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2013-11-13 | — | — | EP | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8450482-B2 | Process for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-([1-(N-methylcarbamoymethyl)piperidin-4-yl]oxy)quinazoline | ASTRAZENECA AB (SE) | 2013-05-28 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8404839-B2 | Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy} quinazoline difumarate Form A | ASTRAZENECA AB (GB) | 2013-03-26 | — | — | US | disclosed |
| US-20120108814-A1 | PROCESS 738 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108814-A1 | PROCESS 738 | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| EP-2421827-A2 | PROCESS FOR THE PREPARATION OF 4-(3-CHLORO-2-FLUORO- ANILINO)-7-METHOXY-6- { [1-(N-METHYLCARBAMOYLMETHYL)- PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2010122340-A2 | PROCESS 738 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010061208-A2 | THERAPEUTIC TREATMENT 555 | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010061208-A2 | THERAPEUTIC TREATMENT 555 | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009138779-A1 | COMBINATION COMPRISING 4- (3-CHLORO-2-FLUOROANILINO) -7-METH0XY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXYJQUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009138779-A1 | COMBINATION COMPRISING 4- (3-CHLORO-2-FLUOROANILINO) -7-METH0XY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXYJQUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286982-A1 | NOVEL SALT-554 | KRAS, NISCH, WASHC4 | PDE4B 1624/4885AR 4308/4885MAP3K5 327/4885 |
| US-20120035363-A1 | CRYSTALLINE 4-(3-CHLORO-2-FLUOROANILINO)-7 METHOXY-6-... | CDK7, CCNC, CDC73 | PDE4B 2719/4885AR 4316/4885MAP3K5 1454/4885 |
| US-20120108814-A1 | PROCESS 738 | CYP2C8, CYP4F8, UGT1A8 | PDE4B 1770/4885AR 4724/4885MAP3K5 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.